Evidence map›Paper›PMID 34518289›Full record

ArticleJournal for immunotherapy of cancer2021

Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.

Eva Bräunlein, Gaia Lupoli, Franziska Füchsl, Esam T Abualrous, Niklas de Andrade Krätzig, Dario Gosmann, Lukas Wietbrock, Sebastian Lange, Thomas Engleitner, Huan Lan and 14 more

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Peripheral CX3CR1Oncoimmunology · 2024
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 3 countries.

Eva BräunleinKlinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München, München, Germany.ORCID 0000-0001-9640-3741
Gaia LupoliKlinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München, München, Germany.
Franziska FüchslKlinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München, München, Germany.ORCID 0000-0001-5069-1442
Esam T AbualrousLaboratory of Protein Biochemistry, Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Niklas de Andrade KrätzigInstitute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Klinikum rechts der Isar der Technischen Universität München, München, Germany.
Dario GosmannKlinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München, München, Germany.ORCID 0000-0002-4973-4801
Lukas WietbrockTUM School of Life Sciences and Center for Integrated Protein Science Munich, Klinikum rechts der Isar der Technischen Universität München, München, Germany.
Sebastian LangeInstitute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Klinikum rechts der Isar der Technischen Universität München, München, Germany.ORCID 0000-0003-0406-1401
Thomas EngleitnerInstitute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Klinikum rechts der Isar der Technischen Universität München, München, Germany.ORCID 0000-0002-7989-681X
Huan LanLaboratory of Protein Biochemistry, Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Stefan AudehmKlinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München, München, Germany.
Manuel EffenbergerInstitute for Medical Microbiology Immunology and Hygiene, Technische Universität München, München, Germany.
Melanie BoxbergInstitute of Pathology, School of Medicine, Klinikum rechts der Isar der Technischen Universität München, München, Germany.ORCID 0000-0001-5989-7922
Katja SteigerInstitute of Pathology, School of Medicine, Klinikum rechts der Isar der Technischen Universität München, München, Germany.ORCID 0000-0002-7269-5433
Yinshui ChangKlinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München, München, Germany.
Kai YuKlinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München, München, Germany.
Cigdem AtayKlinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München, München, Germany.
Florian BassermannKlinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München, München, Germany.ORCID 0000-0003-4435-2609
Wilko WeichertInstitute of Pathology, School of Medicine, Klinikum rechts der Isar der Technischen Universität München, München, Germany.ORCID 0000-0001-6139-8372
Dirk H BuschInstitute for Medical Microbiology Immunology and Hygiene, Technische Universität München, München, Germany.ORCID 0000-0001-8713-093X
Roland RadInstitute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Klinikum rechts der Isar der Technischen Universität München, München, Germany.ORCID 0000-0002-6849-9659
Christian FreundLaboratory of Protein Biochemistry, Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.ORCID 0000-0001-7416-8226
Iris AntesTUM School of Life Sciences and Center for Integrated Protein Science Munich, Klinikum rechts der Isar der Technischen Universität München, München, Germany.ORCID 0000-0002-2241-7187
Angela M KrackhardtKlinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München, München, Germany angela.krackhardt@tum.de.ORCID 0000-0002-4752-0543
TUM Klinikum · DEGerman Cancer Research Center · DELaboratoire de Biochimie · FRCenter for Integrated Protein Science Munich · DEInstitute of Medical Microbiology and Hygiene · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoantigens derived from somatic mutations correlate with therapeutic responses mediated by treatment with immune checkpoint inhibitors. Neoantigens are therefore highly attractive targets for the development of therapeutic approaches in personalized medicine, although many aspects of their quality and associated immune responses are not yet well understood. In a case study of metastatic malignant melanoma, we aimed to perform an in-depth characterization of neoantigens and respective T-cell responses in the context of immune checkpoint modulation.

methodsThree neoantigens, which we identified either by immunopeptidomics or in silico prediction, were investigated using binding affinity analyses and structural simulations. We isolated seven T-cell receptors (TCRs) from the patient's immune repertoire recognizing these antigens. TCRs were compared in vitro by multiparametric analyses including functional avidity, multicytokine secretion, and cross-reactivity screenings. A xenograft mouse model served to study in vivo functionality of selected TCRs. We investigated the patient's TCR repertoire in blood and different tumor-related tissues over 3 years using TCR beta deep sequencing.

resultsSelected mutated peptide ligands with proven immunogenicity showed similar binding affinities to the human leukocyte antigen complex and comparable disparity to their wild-type counterparts in molecular dynamic simulations. Nevertheless, isolated TCRs recognizing these antigens demonstrated distinct patterns in functionality and frequency. TCRs with lower functional avidity showed at least equal antitumor immune responses in vivo. Moreover, they occurred at high frequencies and particularly demonstrated long-term persistence within tumor tissues, lymph nodes and various blood samples associated with a reduced activation pattern on primary in vitro stimulation.

conclusionsWe performed a so far unique fine characterization of neoantigen-specific T-cell responses revealing defined reactivity patterns of neoantigen-specific TCRs. Our data highlight qualitative differences of these TCRs associated with function and longevity of respective T cells. Such features need to be considered for further optimization of neoantigen targeting including adoptive T-cell therapies using TCR-transgenic T cells.

Indexed as

AnimalsAntigens, NeoplasmHumansImmunotherapyMelanomaMiceReceptors, Antigen, T-CellAntigens, NeoplasmReceptors, Antigen, T-Celladaptive immunityadoptiveantigensCD8-positive T-lymphocytesimmunologicimmunotherapyneoplasmreceptors

Identifiers

PMID34518289
PMCPMC8438848
OpenAlexW3200130610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.